Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis

Katherine M. Bever, Luke I. Masha, Fangui Sun, Lauren Stern, Andrea Havasi, John L. Berk, Vaishali Sanchorawala, David C. Seldin, J. Mark Sloan

Research output: Contribution to journalArticle

Abstract

Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single referral center, correlated risk of venous thromboembolism with clinical and laboratory factors, and examined complications of anticoagulation in this population. Sixty-five patients (7%) were documented as having at least one venous thromboembolic event. Eighty percent of these patients had events within one year prior to or following diagnosis. Lower serum albumin was associated with increased risk of VTE, with a hazard ratio of 4.30 (CI 1.60-11.55; P=0.0038) for serum albumin less than 3 g/dL compared to serum albumin greater than 4 g/dL. Severe bleeding complications were observed in 5 out of 57 patients with venous thromboembolism undergoing treatment with anticoagulation. Prospective investigation should be undertaken to better risk stratify these patients and to determine the optimal strategies for prophylaxis against and management of venous thromboembolism.

Original languageEnglish (US)
Pages (from-to)86-90
Number of pages5
JournalHaematologica
Volume101
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Immunoglobulin Light Chains
Venous Thromboembolism
Amyloidosis
Serum Albumin
Hemorrhage
Hemostatics
Referral and Consultation
Retrospective Studies
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Bever, K. M., Masha, L. I., Sun, F., Stern, L., Havasi, A., Berk, J. L., ... Sloan, J. M. (2016). Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica, 101(1), 86-90. https://doi.org/10.3324/haematol.2015.133900

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. / Bever, Katherine M.; Masha, Luke I.; Sun, Fangui; Stern, Lauren; Havasi, Andrea; Berk, John L.; Sanchorawala, Vaishali; Seldin, David C.; Sloan, J. Mark.

In: Haematologica, Vol. 101, No. 1, 01.01.2016, p. 86-90.

Research output: Contribution to journalArticle

Bever, KM, Masha, LI, Sun, F, Stern, L, Havasi, A, Berk, JL, Sanchorawala, V, Seldin, DC & Sloan, JM 2016, 'Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis', Haematologica, vol. 101, no. 1, pp. 86-90. https://doi.org/10.3324/haematol.2015.133900
Bever, Katherine M. ; Masha, Luke I. ; Sun, Fangui ; Stern, Lauren ; Havasi, Andrea ; Berk, John L. ; Sanchorawala, Vaishali ; Seldin, David C. ; Sloan, J. Mark. / Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. In: Haematologica. 2016 ; Vol. 101, No. 1. pp. 86-90.
@article{03056c96f5d74a248ef756319c729220,
title = "Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis",
abstract = "Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single referral center, correlated risk of venous thromboembolism with clinical and laboratory factors, and examined complications of anticoagulation in this population. Sixty-five patients (7{\%}) were documented as having at least one venous thromboembolic event. Eighty percent of these patients had events within one year prior to or following diagnosis. Lower serum albumin was associated with increased risk of VTE, with a hazard ratio of 4.30 (CI 1.60-11.55; P=0.0038) for serum albumin less than 3 g/dL compared to serum albumin greater than 4 g/dL. Severe bleeding complications were observed in 5 out of 57 patients with venous thromboembolism undergoing treatment with anticoagulation. Prospective investigation should be undertaken to better risk stratify these patients and to determine the optimal strategies for prophylaxis against and management of venous thromboembolism.",
author = "Bever, {Katherine M.} and Masha, {Luke I.} and Fangui Sun and Lauren Stern and Andrea Havasi and Berk, {John L.} and Vaishali Sanchorawala and Seldin, {David C.} and Sloan, {J. Mark}",
year = "2016",
month = "1",
day = "1",
doi = "10.3324/haematol.2015.133900",
language = "English (US)",
volume = "101",
pages = "86--90",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis

AU - Bever, Katherine M.

AU - Masha, Luke I.

AU - Sun, Fangui

AU - Stern, Lauren

AU - Havasi, Andrea

AU - Berk, John L.

AU - Sanchorawala, Vaishali

AU - Seldin, David C.

AU - Sloan, J. Mark

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single referral center, correlated risk of venous thromboembolism with clinical and laboratory factors, and examined complications of anticoagulation in this population. Sixty-five patients (7%) were documented as having at least one venous thromboembolic event. Eighty percent of these patients had events within one year prior to or following diagnosis. Lower serum albumin was associated with increased risk of VTE, with a hazard ratio of 4.30 (CI 1.60-11.55; P=0.0038) for serum albumin less than 3 g/dL compared to serum albumin greater than 4 g/dL. Severe bleeding complications were observed in 5 out of 57 patients with venous thromboembolism undergoing treatment with anticoagulation. Prospective investigation should be undertaken to better risk stratify these patients and to determine the optimal strategies for prophylaxis against and management of venous thromboembolism.

AB - Patients with immunoglobulin light chain amyloidosis are at risk for both thrombotic and bleeding complications. While the hemostatic defects have been extensively studied, less is known about thrombotic complications in this disease. This retrospective study examined the frequency of venous thromboembolism in 929 patients with immunoglobulin light chain amyloidosis presenting to a single referral center, correlated risk of venous thromboembolism with clinical and laboratory factors, and examined complications of anticoagulation in this population. Sixty-five patients (7%) were documented as having at least one venous thromboembolic event. Eighty percent of these patients had events within one year prior to or following diagnosis. Lower serum albumin was associated with increased risk of VTE, with a hazard ratio of 4.30 (CI 1.60-11.55; P=0.0038) for serum albumin less than 3 g/dL compared to serum albumin greater than 4 g/dL. Severe bleeding complications were observed in 5 out of 57 patients with venous thromboembolism undergoing treatment with anticoagulation. Prospective investigation should be undertaken to better risk stratify these patients and to determine the optimal strategies for prophylaxis against and management of venous thromboembolism.

UR - http://www.scopus.com/inward/record.url?scp=84952946787&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952946787&partnerID=8YFLogxK

U2 - 10.3324/haematol.2015.133900

DO - 10.3324/haematol.2015.133900

M3 - Article

C2 - 26452981

AN - SCOPUS:84952946787

VL - 101

SP - 86

EP - 90

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -